References
- Malmqvist K, Kahan T, Isaksson H, Östergren J. Regression of left ventricular mass with captopril and metoprolol, and the effects on glucose and lipid metabolism. Blood Press 2001;10:101–110.
- Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151–83.
- Hansson L, Lindholm LH, Niskanen L, et al. Effect ofHangiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP). Lancet 1999; 353: 611–16.
- UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713–20.
- Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Furberg CD. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care 2000; 23: 888–92.
- Harris SB, Zinman B. Primary prevention of type 2 diabetes in high-risk populations. Diabetes Care 2000; 23: 879–81.
- Bennett PH. Primary prevention of NIDDM: a practical reality. Diabetes Metab Rev 1997; 13: 105–11.
- The Heart Outcomes Prevention Evaluation Study Investiga-tors. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–53.